BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 25641567)

  • 1. Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy.
    Onal C; Guler OC; Reyhan M; Yapar AF
    Gynecol Oncol; 2015 Apr; 137(1):40-6. PubMed ID: 25641567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic response of lymph nodes immediately after RT is related with survival outcome of patients with pelvic node-positive cervical cancer using consecutive [18F]fluorodeoxyglucose-positron emission tomography/computed tomography.
    Yoon MS; Ahn SJ; Nah BS; Chung WK; Song HC; Yoo SW; Song JY; Jeong JU; Nam TK
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e491-7. PubMed ID: 22818418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
    Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
    Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of Primary Tumors and Regional Lymph Nodes in Patients with Locally Advanced Cervical Cancer Who Are Treated with Concurrent Chemoradiotherapy.
    Chong GO; Jeong SY; Park SH; Lee YH; Lee SW; Hong DG; Kim JC; Lee YS; Cho YL
    PLoS One; 2015; 10(9):e0137743. PubMed ID: 26368542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy.
    Onal C; Reyhan M; Parlak C; Guler OC; Oymak E
    Int J Gynecol Cancer; 2013 Jul; 23(6):1104-10. PubMed ID: 23792605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer.
    Cima S; Perrone AM; Castellucci P; Macchia G; Buwenge M; Cammelli S; Cilla S; Ferioli M; Ferrandina G; Galuppi A; Salizzoni E; Rubino D; Fanti S; De Iaco P; Morganti AG
    Int J Gynecol Cancer; 2018 Mar; 28(3):575-580. PubMed ID: 29372911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
    Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
    Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of the Sum of Metabolic Tumor Volume of Primary Tumor and Lymph Nodes Using 18F-FDG PET/CT in Patients With Cervical Cancer.
    Hong JH; Min KJ; Lee JK; So KA; Jung US; Kim S; Eo JS
    Medicine (Baltimore); 2016 Mar; 95(9):e2992. PubMed ID: 26945420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer.
    Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
    Cancer; 2010 Mar; 116(6):1469-75. PubMed ID: 20108309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic values of ADC
    Akkus Yildirim B; Onal C; Erbay G; Cem Guler O; Karadeli E; Reyhan M; Koc Z
    J Obstet Gynaecol; 2019 Feb; 39(2):224-230. PubMed ID: 30354907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardized uptake value and metabolic tumor volume measured by ¹⁸F FDG PET/CT are sensitive biomarkers for the presence of lymph node metastasis in patients with cervical carcinoma.
    Vural GU; Akkas BE; Demirel BB
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):268-73. PubMed ID: 25018135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era.
    Vargo JA; Kim H; Choi S; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Beriwal S
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1091-8. PubMed ID: 25303889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implication of retrocrural lymph node involvement revealed by (18)F-FDG PET/CT in patients with uterine cervical cancer.
    Im HJ; Yoon HJ; Lee ES; Kim TS; Kim JY; Chung JK; Kim SK; Park SY
    Nucl Med Commun; 2014 Mar; 35(3):268-75. PubMed ID: 24253568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer?
    Akkas BE; Demirel BB; Dizman A; Vural GU
    Ann Nucl Med; 2013 Oct; 27(8):756-63. PubMed ID: 23793926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
    Dag Z; Yilmaz B; Dogan AK; Aksan DU; Ozkurt H; Kızılkaya HO; Arslan D
    Brachytherapy; 2019; 18(2):154-162. PubMed ID: 30594422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical response of pelvic and para-aortic lymphadenopathy to a radiation boost in the definitive management of locally advanced cervical cancer.
    Rash DL; Lee YC; Kashefi A; Durbin-Johnson B; Mathai M; Valicenti R; Mayadev JS
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):317-22. PubMed ID: 23906933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?
    Voglimacci M; Gabiache E; Lusque A; Ferron G; Ducassou A; Querleu D; Motton S; Chantalat E; Courbon F; Martinez A
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1551-1559. PubMed ID: 30729273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
    Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive chemoradiotherapy.
    Onal C; Reyhan M; Guler OC; Yapar AF
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1336-42. PubMed ID: 24562649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.